gland, mammary tissue, lungs, kidneys, liver, and placenta. Compared with maternal tissues, a relatively low level of radioactivity was detected in fetal tissues. The concentrations of dasatinibequivalents in fetal liver and kidneys were <13% of the respective maternal organs. The C max of dasatinib-equivalents in fetal blood was approximately 39% of that in maternal blood; however, the AUC values were comparable. Fetal brain/blood ratios of C max and AUC 0-inf were approximately 1.58 and 1.48, respectively, which were much greater than the maternal ratios of 0.12 and 0.13. In summary, dasatinib was extensively distributed in maternal tissues and secreted into milk, but its penetration into the adult brain was limited. Transporters may be involved in mediating dasatinib distribution in the adult rat, whereas in the fetus, tissue and blood exposures were similar, suggesting that distribution in the fetus is predominantly mediated by diffusion.Dasatinib (SPRYCEL, BMS-354825) ( Fig. 1) is a potent, broadspectrum ATP-competitive inhibitor of five critical oncogenic tyrosine kinase families, including BCR-ABL, SRC, c-KIT, plateletderived growth factor  receptor, and ephrin receptor kinases (Lombardo et al., 2004;Schittenhelm et al., 2006;Tokarski et al., 2006). These kinases are involved in multiple forms of human malignancies (Daley et al., 1990;Lugo et al., 1990). Dasatinib is approximately 500-fold more potent than imatinib in inhibiting BCR-ABL. It binds to both the active and the inactive conformations of BCR-ABL, whereas imatinib only binds to the inactive state Talpaz et al., 2006;Tokarski et al., 2006;Quintas-Cardama et al., 2007). In clinical trials, dasatinib induced rapid and long-lasting major hematologic and cytogenetic responses in patients with imatinibresistant or intolerant blast crisis chronic myeloid leukemia (Guilhot et al., 2007;Hochhaus et al., 2007). Dasatinib also induced molecular responses, reducing BCR-ABL/ABL transcript ratios. Dasatinib is currently marketed for the treatment of adults with chronic, accelerated, or blast-phase chronic myeloid leukemia with resistance or intolerance to previous therapy including imatinib mesylate, and for the treatment of adults with Philadelphia chromosome positive (Ph ϩ ) acute lymphoblastic leukemia and lymphoid blast chronic myeloid leukemia with resistance or intolerance to previous therapy. Dasatinib is also under clinical development for the treatment of solid tumors.Dasatinib showed high intrinsic permeability in the Caco-2 cell model; however, the efflux ratio in this system was approximately 2-fold, suggesting that the compound may be a substrate for an intestinal efflux transporter (Kamath et al., 2008). Dasatinib showed a high volume of distribution (Ͼ3 l/kg) in each of the animal species (Kamath et al., 2008) and was highly metabolized in rats, monkeys, and humans (Christopher et al., 2008a,b). After intravenous administration of [14 C]dasatinib to bile duct-cannulated monkeys, approximately 10 and 67% of the dose was recovered in urine and b...